Cargando…

Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study

PURPOSE: To evaluate the efficacy of maintenance apatinib after chemotherapy for extensive-stage (ED) small-cell lung cancer (SCLC). PATIENTS AND METHODS: This was a retrospective analysis of 23 cases of extensive-stage SCLC admitted to the Affiliated Cancer Hospital of Zhengzhou University from Jan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Xiangtao, Wang, Qiming, Wang, Huijuan, Li, Peng, Zhang, Guowei, Zhang, Mina, Zheng, Xuanxuan, Yang, Jinpo, Zhang, Xiaojuan, Ma, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326003/ https://www.ncbi.nlm.nih.gov/pubmed/30293117 http://dx.doi.org/10.1007/s00432-018-2764-8

Ejemplares similares

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
por: ZHANG, Guowei, et al.
Publicado: (2022)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
por: Wang, Huijuan, et al.
Publicado: (2019)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study
por: Zhang, Cuicui, et al.
Publicado: (2021)

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study
por: Wang, Huijuan, et al.
Publicado: (2023)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer
por: Luo, Hao, et al.
Publicado: (2019)

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
por: Wang, Jijin, et al.
Publicado: (2022)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
por: Liu, Zhaoyun, et al.
Publicado: (2021)

Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
por: Zhang, Yonglei, et al.
Publicado: (2021)

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
por: He, Zhen, et al.
Publicado: (2021)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
por: Wang, Mingqi, et al.
Publicado: (2021)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Radiation Therapy in Extensive Stage Small Cell Lung Cancer
por: Jeremic, Branislav, et al.
Publicado: (2017)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Cui, Lixuan, et al.
Publicado: (2021)

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study
por: Xia, Wei-Li, et al.
Publicado: (2022)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
por: Meng, Xiangrui, et al.
Publicado: (2020)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
por: Wang, Yonggang, et al.
Publicado: (2022)

Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
por: Xia, Hui, et al.
Publicado: (2021)

Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Controversial Area
por: Xue, Shuyu, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Personalized treatment of extensive stage small cell lung cancer: A case report and literature review
por: Wang, Huaiyu, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
por: Aly, Ragia, et al.
Publicado: (2020)

Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma
por: Shionoya, Yosuke, et al.
Publicado: (2021)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
por: Kang, Shuo, et al.
Publicado: (2022)

Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports
por: Jin, Mei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0u8ltpsgk8cggtd1u5l2c27uk7